Urokinase treats respiratory diseases

(1) local thrombolysis of urokinase for the treatment of acute massive pulmonary thrombus

Pulmonary angiography confirmed that intravenous urokinase was more effective than intravenous heparin in the treatment of pulmonary thromboembolism at 12 hours.

(2) different combinations of urokinase, LMWH and warfarin in the treatment of pulmonary embolism

Objective to observe the clinical efficacy and safety of low molecular weight heparin, urokinase or warfarin in the treatment of pulmonary embolism (PE). The study showed that 63 patients with PE were randomly divided into group A, group B and group C, each with 21 cases. Group A received urokinase, low-molecular-weight heparin and warfarin in combination, group B only received urokinase and warfarin in combination, and group C only received low-molecular-weight heparin and warfarin in combination. Results the total effective rate of group A was 90.48% higher than that of group B and group C, which were 71.43% and 66.67% respectively. The difference was statistically significant (P < 0.05). Conclusion the combination of urokinase, low molecular weight heparin and warfarin in the treatment of PE is effective, safe and worthy of clinical application.